Ruwen Yang

Dr. Ruwen Yang

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2021 in Clinical and Translational Medicine
Verified
Journal Article
Open access
PDF file
YTYue Tao
Yue Tao
RYRuwen Yang
Ruwen Yang
CWChen Wen
Chen Wen
JFJue Fan
Jue Fan
JMJing Ma
Jing Ma
XMXi Mo
Xi Mo
Click on the article title to read more.

25 January 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
CSChristoph Schifflers
Christoph Schifflers
SZSamantha Zottnick
Samantha Zottnick
JFJonas D. Förster
Jonas D. Förster
SKSebastian Kruse
Sebastian Kruse
RYRuwen Yang
Ruwen Yang
ARAngelika Riemer
Angelika Riemer
Head and neck squamous cell carcinomas (HNSCC) caused by infections with high-risk human papillomaviruses (HPV) are responsible for an increasing number of head and neck cancers, particularly in the oropharynx. Despite the significant biological differences between HPV-driven and HPV-negative HNSCC, treatment strategies are similar and not HPV targeted. HPV-driven HNSCC are known to be more sensitive to treatment, particularly to radiotherapy, which is at least partially due to HPV-induced immunogenicity. The development of novel therapeutic strategies that are specific for HPV-driven cancers requires tumor models that reflect as closely as possible the characteristics and complexity of human tumors and their response to treatment. Current HPV-positive cancer models lack one or more hallmarks of their human counterpart. This study presents the development of a new HPV16 oncoprotein-dependent tumor model in MHC-humanized mice, modeling the major biologic features of HPV-driven tumors and presenting HLA-A2-restricted HPV16 epitopes. Furthermore, this model was developed to be orthotopic (base of tongue). Thus, it also reflects the correct tumor microenvironment of HPV-driven HNSCC. The cancer cells are implanted in a manner that allows the exact control of the anatomical location of the developing tumor, thereby homogenizing tumor growth. In conclusion, the new model is suited to study HPV16-specific therapeutic vaccinations and other immunotherapies, as well as tumor-targeted interventions, such as surgery or radiotherapy, or a combination of all these modalities.